证券之星消息，微芯生物(688321)02月10日在投资者关系平台上答复投资者关心的问题。 投资者：董秘您好！贵司西奥罗尼单药三线小细胞肺癌三期临床失败，请问具体原因是什么？我们知道该药是多靶点的，是不是其中某一个或两个靶点通路出现耐药性？是否会影响该药其他适应症的开发进度？敬请回复！谢谢！顺颂蛇年商祺！

According to the classical paradigm, CCR7 is a homing chemokine receptor that grants normal lymphocytes access to secondary lymphoid tissues such as lymph nodes or spleen. As such, in most ...

We produce expert, up-to-date and high-quality information for people affected by lymphoma. Our information is based on the latest evidence and is reviewed every 2 to 3 years. It is written in plain ...

尊敬的患者和患者家属： 同济医院正在开展一项免费的“III期、开放标签、随机、多中心研究以评估戈利昔替尼对比研究者选择治疗在复发难治性外 ...

PTCL 的主要类型包括血管免疫母细胞性 T 细胞淋巴瘤（AITL，angioimmunoblastic T-cell lymphoma ）15 例（32%）、间变性大细胞淋巴瘤（ALCL，anaplastic large cell lymphoma ）12 例（26%）和外周 T 细胞淋巴瘤非特指型（PTCL-NOS，peripheral T-cell lymphoma not other ...